Trial reportParasite (Paris, France)2016
Efficacy of oral afoxolaner for the treatment of canine generalised demodicosis.
Trial report in Parasite (Paris, France), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- A systematic review of moxidectin as a treatment for parasitic infections in mammalian species.Parasitology research · 2021Pooled it
- Critically appraised topic for the most effective and safe treatment for canine generalised demodicosis.BMC veterinary research · 2019Pooled it
- Assessment of the insecticidal activity of afoxolaner against Aedes aegypti in dogs treated with NexGardParasite (Paris, France) · 2017Trial
- Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei.Parasite (Paris, France) · 2016Trial
- Efficacy of afoxolaner or a combination of afoxolaner and milbemycin oxime against fleas, ticks, lice and/or intestinal nematodes in dogs naturally infested in two urban areas in Brazil.Parasites & vectors · 2026Article
- Investigation of serum acute-phase protein levels and hematological and biochemical parameters in dogs with generalized demodicosis.BMC veterinary research · 2026Article
- Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs.Veterinary dermatology · 2025Article
- Article
- Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife.International journal for parasitology. Drugs and drug resistance · 2023Review
- Afoxolaner (NexGard®) in pet snakes for the treatment and control of Ophionyssus natricis (Mesostigmata: Macronyssidae).Parasites & vectors · 2023Article
- Isoxazolines for treating canine demodicosis, sarcoptic mange (scabies), and lice infestation.The Canadian veterinary journal = La revue veterinaire canadienne · 2022Article
- Efficacy of afoxolaner (NexGard®) against natural infestations with Trichodectes canis in dogs under field conditions.Parasites & vectors · 2022Article
- Fluralaner 5.46% (w/w) flavored chewable tablet (BravectoParasites & vectors · 2022Article
- A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis.Veterinary research communications · 2022Article
- Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against ear mite (Otodectes cynotis) infestations in cats.Parasite (Paris, France) · 2021Article
- Insecticidal efficacy of afoxolaner against bedbugs, Cimex lectularius, when administered orally to dogs.Parasite (Paris, France) · 2021Article
- Protecting dogs and cats against the Australian paralysis tick,Current research in parasitology & vector-borne diseases · 2021Review
- Hyalomma anatolicum resistance against ivermectin and fipronil is associated with indiscriminate use of acaricides in southwestern Balochistan, Pakistan.Parasitology research · 2021Article
- A European field assessment of the efficacy of fluralaner (BravectoParasites & vectors · 2020Article
- Afoxolaner as a Treatment for a NovelFrontiers in veterinary science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of oral treatment with a chewable tablet containing afoxolaner 2.27% w/w (NexGard(®), Merial) administered orally was assessed in eight dogs diagnosed with generalised demodicosis and compared with efficacy in eight dogs under treatment with a topical combination of imidacloprid/moxidectin (Advocate(®), Bayer). Afoxolaner was administered at the recommended dose (at least 2.5 mg/kg) on Days 0, 14, 28 and 56. The topical combination of imidacloprid/moxidectin was given at the same intervals at the recommended concentration. Clinical examinations and deep skin scrapings were performed every month in order to evaluate the effect on mite numbers and the resolution of clinical signs. The percentage reductions of mite counts were 99.2%, 99.9% and 100% on Days 28, 56 and 84, respectively, in the afoxolaner-treated group, compared to 89.8%, 85.2% and 86.6% on Days 28, 56 and 84 in the imidacloprid/moxidectin-treated group. Skin condition of the dogs also improved significantly from Day 28 to Day 84 in the afoxolaner-treated group. Mite reductions were significantly higher on Days 28, 56 and 84 in the afoxolaner-treated group compared to the imidacloprid/moxidectin-treated group. The results of this study demonstrated that afoxolaner, given orally, was effective in treating dogs with generalised demodicosis within a two-month period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.